Level C· Early human research exploring benefitsProspective StudyPubMed

Prevalence of endogenous CD34+ adipose stem cells predicts human fat graft retention in a xenograft model.

Philips BJ., Grahovac TL., Valentin JE., Chung CW., Bliley JM., Pfeifer ME.

Prospective Study on Face & Skin, published in Plast Reconstr Surg (2013) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Plast Reconstr Surg (2013)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
23783061
PMCID
PMC4165082
DOI
10.1097/PRS.0b013e31829fe5b1
Citations
86

Abstract (original English)

Fat grafting is a promising technique for soft-tissue augmentation, although graft retention is highly unpredictable and factors that affect graft survival have not been well defined. Because of their capacity for differentiation and growth factor release, adipose-derived stem cells may have a key role in graft healing. The authors' objective was to determine whether biological properties of adipose-derived stem cells present within human fat would correlate with in vivo outcomes of graft volume retention. Lipoaspirate from eight human subjects was processed using a standardized centrifugation technique and then injected subcutaneously into the flanks of 6-week-old athymic nude mice. Graft masses and volumes were measured, and histologic evaluation, including CD31+ staining for vessels, was performed 8 weeks after transplantation. Stromal vascular fraction isolated at the time of harvest from each subject was analyzed for surface markers by multiparameter flow cytometry, and also assessed for proliferation, differentiation capacity, and normoxic/hypoxic vascular endothelial growth factor secretion. Wide variation in percentage of CD34+ progenitors within the stromal vascular fraction was noted among subjects and averaged 21.3 ± 15 percent (mean ± SD). Proliferation rates and adipogenic potential among stromal vascular fraction cells demonstrated moderate interpatient variabilit

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AdipogenesisAdultAdult Stem CellsAnimalsAntigens, CD34Cell DifferentiationFemaleGraft SurvivalHumansInjections, Subcutaneous

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research